We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
-11.47%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$186M
AUM Growth
-$94.7M
Cap. Flow
-$67.3M
Cap. Flow %
-36.29%
Top 10 Hldgs %
37.92%
Holding
69
New
7
Increased
10
Reduced
25
Closed
21

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.04M
2
DHR icon
Danaher
DHR
+$4.61M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.66M
4
ELAN icon
Elanco Animal Health
ELAN
+$2.74M
5
SNN icon
Smith & Nephew
SNN
+$2.73M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$8.69M
2
AET
Aetna Inc
AET
+$7.1M
3
ALGN icon
Align Technology
ALGN
+$6.85M
4
CELG
Celgene Corp
CELG
+$4.47M
5
DGX icon
Quest Diagnostics
DGX
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 90.94%
2 Energy 2.02%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOH icon
26
Molina Healthcare
MOH
$10.2B
$3.49M 1.88%
30,000
-20,000
-40% -$2.62M
CNC icon
27
Centene
CNC
$32.1B
$3.4M 1.83%
58,900
-31,100
-35% -$2.08M
TMO icon
28
Thermo Fisher Scientific
TMO
$224B
$3.36M 1.81%
15,000
-5,000
-25% -$1.17M
A icon
29
Agilent Technologies
A
$42.2B
$3.18M 1.71%
47,148
+32,148
+214% +$2.16M
BIO icon
30
Bio-Rad Laboratories Class A
BIO
$9.53B
$2.9M 1.56%
12,500
-7,500
-38% -$2.01M
TEVA icon
31
Teva Pharmaceuticals
TEVA
$42.5B
$2.85M 1.54%
185,000
-15,000
-8% -$308K
SNN icon
32
Smith & Nephew
SNN
$12.6B
$2.84M 1.53%
+76,000
New +$2.73M
BHC icon
33
Bausch Health
BHC
$2.33B
$2.77M 1.49%
150,000
-20,000
-12% -$476K
ELAN icon
34
Elanco Animal Health
ELAN
$11.4B
$2.64M 1.42%
+83,637
New +$2.74M
AMED
35
DELISTED
Amedisys
AMED
$2.34M 1.26%
+20,000
New +$2.36M
INCY icon
36
Incyte
INCY
$24.5B
$2.23M 1.2%
35,000
-5,000
-13% -$325K
SRPT icon
37
Sarepta Therapeutics
SRPT
$1.92B
$2.18M 1.18%
20,000
-5,000
-20% -$625K
ZBH icon
38
Zimmer Biomet
ZBH
$18.5B
$2.07M 1.12%
20,600
-20,600
-50% -$2.32M
MCK icon
39
McKesson
MCK
$105B
$1.66M 0.89%
15,000
-7,500
-33% -$935K
VTRS icon
40
Viatris
VTRS
$18.7B
$1.54M 0.83%
56,186
-38,814
-41% -$1.26M
LOXO
41
DELISTED
Loxo Oncology, Inc
LOXO
$1.4M 0.76%
10,000
-5,000
-33% -$759K
SAGE
42
DELISTED
Sage Therapeutics
SAGE
$958K 0.52%
10,000
– –
DXCM icon
43
DexCom
DXCM
$33.8B
$899K 0.48%
30,000
-50,000
-63% -$1.59M
COR icon
44
Cencora
COR
$63.7B
$744K 0.4%
10,000
-27,500
-73% -$2.37M
AGIO icon
45
Agios Pharmaceuticals
AGIO
$1.95B
$692K 0.37%
15,000
-5,000
-25% -$309K
HAE icon
46
Haemonetics
HAE
$3.97B
$500K 0.27%
5,000
-15,000
-75% -$1.58M
GWPH
47
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$487K 0.26%
5,000
-22,500
-82% -$2.95M
MRNA icon
48
Moderna
MRNA
$24.2B
$382K 0.21%
+25,000
New +$411K
ALGN icon
49
Align Technology
ALGN
$12.3B
– –
-17,500
Closed -$6.85M
BLUE
50
DELISTED
bluebird bio
BLUE
– –
-579
Closed -$1.09M
1
2
3

Similar funds

AFP
ATX Financial Planning Austin, Texas $132M AUM
TCPW
Twin City Private Wealth Winston-Salem, North Carolina $132M AUM 11.31% 1-Year Est. Return
PCGDR
Pangea Capital Gestao de Recursos Rio De Janeiro $131M AUM
ACM
Alcosta Capital Management San Ramon, California $131M AUM 34.7% 1-Year Est. Return
9C
9823 Capital Dallas, Texas $132M AUM
STFP
Signal Tree Financial Partners Copley, Ohio $132M AUM 15.43% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return

Sivik Global Healthcare's Q4 2018 Portfolio in Review

As of Q4 2018, Sivik Global Healthcare held 69 positions worth $186M, down 34% from $280M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sivik Global Healthcare withdrew a net $67.3M in Q4 2018, closing 21 positions and reducing 25 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $8.69M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Energy and Financials.

Against the trend, Sivik Global Healthcare opened a new position in State Street SPDR S&P Biotech ETF worth $5.38M.

  • Sivik Global Healthcare's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 75,000 shares worth $5.38M.
  • Sivik Global Healthcare added most to Agilent Technologies in Q4 2018, an estimated $2.16M increase.
  • Sivik Global Healthcare's biggest Q4 2018 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $2.95M.
  • Sivik Global Healthcare fully exited Bristol-Myers Squibb in Q4 2018, selling an estimated $8.69M.
  • Sivik Global Healthcare's ten largest holdings make up 38% of its $186M portfolio in Q4 2018.
  • Sivik Global Healthcare opened 7 new positions and closed 21 in Q4 2018.
  • Sivik Global Healthcare's portfolio value fell 34% quarter-over-quarter to $186M.

Based on Sivik Global Healthcare's 13F filing for Q4 2018, filed 12 Feb 2019.